Understand the source comparison
Best Peptides for Sarcopenia: Clinical Comparison
The table below compares the most researched peptide classes for sarcopenia based on mechanism, evidence quality, and practical considerations for research application. Ipamorelin Selective GHSR-1a agonist; stimulates pulsatile GH release Phase II human trials
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below compares the most researched peptide classes for sarcopenia based on mechanism, evidence quality, and practical considerations for research application.
- Ipamorelin
- Selective GHSR-1a agonist; stimulates pulsatile GH release
- Phase II human trials; established safety profile
- Daily to twice-daily subcutaneous
- Requires intact pituitary function; effects depend on dietary protein
- Strong foundational choice for GH pathway research; well-tolerated with consistent pharmacokinetics
- CJC-1295 NO DAC
- GHRH analogue; sustained GH and IGF-1 elevation
- Phase II human data showing lean mass gains
- 2–3 times weekly subcutaneous
- Longer half-life increases risk of supraphysiological GH levels
- Best used in combination with pulsatile secretagogue to mimic natural GH patterns
- MK-677
- Orally bioavailable ghrelin mimetic; 24-hour GH elevation
- 12-month human trial data in elderly populations
- Once daily oral
- Appetite stimulation may complicate body composition goals
- Most practical for long-term research due to oral route and once-daily dosing
- IGF-1 LR3
- Direct IGF-1 receptor agonist; bypasses GH-to-IGF-1 conversion
- Strong preclinical data; limited human sarcopenia trials
- Daily subcutaneous for 4–6 week cycles
- Concerns about off-target receptor activation in non-muscle tissues
- Powerful direct anabolic agent but requires careful cycle management
- TB-500
- Satellite cell activator; promotes muscle repair and reduces inflammation
- Robust animal models; minimal human sarcopenia data
- Twice weekly subcutaneous
- Lacks Phase II human data in aging populations
- Promising adjunct for repair-focused research but not a standalone anabolic
- BPC-157
- Angiogenic and tissue repair peptide
- Preclinical only; no human sarcopenia studies
- Daily subcutaneous
- Mechanism in muscle tissue not fully characterized
- Interesting preclinical profile but insufficient data to recommend for sarcopenia-specific research